Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TatD DNase domain containing 1 pseudogene 1 (TATDN1P1) is classified as a *pseudogene*, meaning it is a genomic locus resembling a genuine gene, but typically harbors sequence disruptions (such as frameshifts or stop codons) that preclude translation into a functional protein[2]. It is annotated in human genomic databases (NCBI Gene: 728737, Ensembl: ENSG00000234369), but there is no evidence for protein expression or functional activity. Pseudogenes generally do not serve as therapeutic targets, and there is limited or no literature describing biological, pathological, or pharmacological roles specific to TATDN1P1. Unlike some pseudogenes (e.g., PTENP1), which have described regulatory roles through non-coding RNA mechanisms[1][4], there is currently no evidence that TATDN1P1 is involved in gene regulation, disease processes, or therapeutic response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TatD DNase domain containing 1 pseudogene 1 (TATDN1P1).